Current whole-body MRI applications in the neurofibromatosis: NF1, NF2, and schwannomatosis

Neurology

Volumn 87, Issue 7, 2016, Pages S31-S39

  Ahlawat, Shivani ^a   Fayad, Laura M ^a   Khan, Muhammad Shayan ^d   Bredella, Miriam A ^e   Harris, Gordon J ^e   Evans, D Gareth ^f   Farschtschi, Said ^g   Jacobs, Michael A ^a,b   Chhabra, Avneesh ^h   Salamon, Johannes M ^g   Wenzel, Ralph ⁱ   Mautner, Victor F ^g   Dombi, Eva ^j   Cai, Wenli ^e   Plotkin, Scott R ^e   Blakeley, Jaishri O ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d KHYBER TEACHING HOSPITAL   (Pakistan)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ Radiological Practice Altona   (Germany)

^j NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEASIBILITY STUDY; HUMAN; META ANALYSIS; NEUROFIBROMATOSIS; PRIORITY JOURNAL; REPRODUCIBILITY; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TUMOR VOLUME; WHOLE BODY MRI; CLINICAL TRIAL (TOPIC); CONSENSUS DEVELOPMENT; DIAGNOSTIC IMAGING; MULTICENTER STUDY (TOPIC); NEURILEMOMA; NEUROFIBROMATOSIS TYPE 1; NEUROFIBROMATOSIS TYPE 2; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PROCEDURES; SKIN TUMOR; WHOLE BODY IMAGING;

CLINICAL TRIALS AS TOPIC; HUMANS; MAGNETIC RESONANCE IMAGING; MULTICENTER STUDIES AS TOPIC; NEURILEMMOMA; NEUROFIBROMATOSES; NEUROFIBROMATOSIS 1; NEUROFIBROMATOSIS 2; SKIN NEOPLASMS; WHOLE BODY IMAGING;

EID: 85003723261     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002929     Document Type: Article

References (37)

1. Toledano-Massiah S, Luciani A, Itti E, et al. Whole-body diffusion-weighted imaging in Hodgkin lymphoma and diffuse large B-cell lymphoma. Radiographics 2015;35:747-764.
2. Pasoglou V, Michoux N, Peeters F, et al. Whole-body 3D T1-weighted MR imaging in patients with prostate cancer: feasibility and evaluation in screening for metastatic disease. Radiology 2015;275:155-166.
3. Friedman DN, Lis E, Sklar CA, et al. Whole-body magnetic resonance imaging (WB-MRI) as surveillance for subsequent malignancies in survivors of hereditary retinoblastoma: A pilot study. Pediatr Blood Cancer 2014;61: 1440-1444.
4. Ciliberto M, Maggi F, Treglia G, et al. Comparison between whole-body MRI and fluorine-18-fluorodeoxyglucose PET or PET/CT in oncology: A systematic review. Radiol Oncol 2013;47:206-218.
5. Schlemmer HP, Schäfer J, Pfannenberg C, et al. Fast whole-body assessment of metastatic disease using a novel magnetic resonance imaging system: initial experiences. Invest Radiol 2005;40:64-71.
6. Attariwala R, Picker W. Whole body MRI: improved lesion detection and characterization with diffusion weighted techniques. J Magn Reson Imaging 2013;38: 253-268.
7. Mulvihill JJ, Parry DM, Sherman JL, Pikus A, Kaiser-Kupfer MI, Eldridge R. NIH conference: neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis): an update. Ann Intern Med 1990;113:39-52.
8. Baser ME, Friedman JM, Wallace AJ, Ramsden RT, Joe H, Evans DG. Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology 2002;59:1759-1765.
9. MacCollin M, Chiocca EA, Evans DG, et al. Diagnostic criteria for schwannomatosis. Neurology 2005;64:1838-1845.
10. Merker VL, Bredella MA, Cai W, et al. Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis. Am J Med Genet A 2014;164A:1431-1437.
11. Nguyen R, Jett K, Harris GJ, Cai W, Friedman JM, Mautner VF. Benign whole body tumor volume is a risk factor malignant peripheral nerve sheath tumors in neurofibromatosis type 1. J Neurooncol 2014;116:307-313.
12. Urban T, Lim R, Merker VL, et al. Anatomic and metabolic evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis 1 using whole-body MRI and (18)F-FDG PET fusion. Clin Nucl Med 2014;39: e301-e307.
13. Fayad LM, Blakeley J, Plotkin S, Widemann B, Jacobs MA. Whole body MRI at 3T with quantitative diffusion weighted imaging and contrast-enhanced sequences for the characterization of peripheral lesions in patients with neurofibromatosis type 2 and schwannomatosis. ISRN Radiol 2013;2013:627932.
14. Derlin T, Tornquist K, Münster S, et al. Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Clin Nucl Med 2013; 38:e19-e25.
15. Nguyen R, Dombi E, Widemann BC, et al. Growth dynamics of plexiform neurofibromas: A retrospective cohort study of 201 patients with neurofibromatosis 1. Orphanet J Rare Dis 2012;7:75.
16. Plotkin SR, Bredella MA, Cai W, et al. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS One 2012;7:e35711.
17. Kluwe L, Nguyen R, Vogt J, et al. Internal tumor burden in neurofibromatosis type I patients with large NF1 deletions. Genes Chromosomes Cancer 2012;51:447-451.
18. Nguyen R, Kluwe L, Fuensterer C, Kentsch M, Friedrich RE, Mautner VF. Plexiform neurofibromas in children with neurofibromatosis type 1: frequency and associated clinical deficits. J Pediatr 2011;159:652-655.e2.
19. Cai W, Kassarjian A, Bredella MA, et al. Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images. Radiology 2009;250:665-673.
20. Van Meerbeeck SF, Verstraete KL, Janssens S, Mortier G. Whole body MR imaging in neurofibromatosis type 1. Eur J Radiol 2009;69:236-242.
21. Mautner VF, Asuagbor FA, Dombi E, et al. Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. Neuro Oncol 2008;10:593-598.
22. Jaremko JL, MacMahon PJ, Torriani M, et al. Wholebody MRI in neurofibromatosis: incidental findings and prevalence of scoliosis. Skeletal Radiol 2012;41:917-923.
23. Karmazyn B, Cohen MD, Jennings SG, Robertson KA. Marrow signal changes observed in follow-up whole-body MRI studies in children and young adults with neurofibromatosis type 1 treated with imatinib mesylate (Gleevec) for plexiform neurofibromas. Pediatr Radiol 2012;42:1218-1222.
24. Farschtschi SC, Dombi E, Widemann B, Fünsterer C, Mautner VF. Comparability of 1.5T and 3.0T MRIvolumetrics in neurofibromatosis type 1. Presented at the 2013 NF Conference, Monterey, CA.
25. Brauck K, Zenge MO, Vogt FM, et al. Feasibility of whole-body MR with T2-and T1-weighted real-time steady-state free precession sequences during continuous table movement to depict metastases. Radiology 2008; 246:910-916.
26. Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 2014;270:834-841.
27. Subhawong TK, Durand DJ, Thawait GK, Jacobs MA, Fayad LM. Characterization of soft tissue masses: can quantitative diffusion weighted imaging reliably distinguish cysts from solid masses? Skeletal Radiol 2013;42: 1583-1592.
28. Demehri S, Belzberg A, Blakeley J, Fayad LM. Conventional and functional MR imaging of peripheral nerve sheath tumors: initial experience. AJNR 2014;35:1615-1620.
29. Dombi E, Ardern-Holmes SL, Babovic-Vuksanovic D, et al. Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology 2013;81(21 suppl 1): S33-S40.
30. Widemann BC, Blakeley JO, Dombi E, et al. Conclusions and future directions for the ReiNS International Collaboration. Neurology 2013;81(21 suppl 1):S41-S44.
31. Harris GJ, Plotkin SR, MacColllin M, et al. Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II. Neurosurgery 2008; 62:1314-1319.
32. Hopper KD, Kasales CJ, Van Slyke MA, Schwartz TA, TenHave TR, Jozefiak JA. Analysis of interobserver and intraobserver variability in CT tumor measurements. AJR Am J Roentgenol 1996;167:851-854.
33. Dempsey MF, Condon BR, Hadley DM. Measurement of tumor "size" in recurrent malignant glioma: 1D, 2D, or 3D? AJNR Am J Neuroradiol 2005;26:770-776.
34. Erasmus JJ, Gladish GW, Broemeling L, et al. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 2003;21:2574-2582.
35. Chhabra A, Thakkar RS, Andresisek G, et al. Anatomic MR imaging and functional diffusion tensor imaging of peripheral nerve tumors and tumorlike conditions. AJNR Am J Neuroradiol 2013;34: 802-807.
36. Solomon J, Warren K, Dombi E, Patronas N, Widemann B: Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging. Comput Med Imaging Graph 2004;28:257-265.
37. Dombi E, Solomon J, Gillespie AJ, et al. NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight. Neurology 2007;68:643-647.